Characteristic | Total (n = 57) | AL group (n = 19) | QD group (n = 38) | p value |
---|---|---|---|---|
Demographics | ||||
Male gender (n, %) | 51 (89%) | 18 (95%) | 33 (87%) | 0.65a |
Age (mean in years, SD) | 41.2 (9.7%) | 40 (10) | 42 (10) | 0.63b |
Portuguese nationality (n, %) | 49 (86%) | 18 (95%) | 31 (81%) | 0.25c |
Country of malaria acquisition | 0.48c | |||
Angola (n, %) | 37 (65%) | 11 (58%) | 26 (68%) | |
Mozambique (n, %) | 7 (12.3%) | 2 (11%) | 5 (13%) | |
Other (n, %) | 13 (22.8%) | 6 (31.6) | 7 (18.4%) | |
Past history of malaria (n, %) | 23 (49.3%) | 5 (26%) | 18 (47%) | 0.16c |
Parasitaemia | ||||
Initial parasitaemia (n, %) (median, IQR) | 1.0 (1.5) | 0.5 (0.9) | 1.0 (1.5) | 0.03 d |
Days until symptoms resolution (median, IQR) | 2 (2) | 2 (1) | 2 (2) | 0.89d |
Days until no parasitaemia (median, IQR) | 2 (2) | 2 (2) | 3 (3) | 0.09d |
Liver panele | ||||
At diagnosis | ||||
Initial AST (median, IQR) | 44 (29.5) | 46 (41) | 42 (26) | 0.99d |
Initial ALT (median,IQR) | 41 (52) | 32 (52) | 44 (53) | 0.50d |
Initial GGT (median, IQR) | 51 (91) | 48 (100) | 52 (87) | 0.84d |
Initial AP (median, IQR) | 67 (32.5) | 77 (32) | 60 (30) | 0.13d |
Initial total bilirubin (median, IQR) | 1.2 (0.7) | 1.2 (0.7) | 1.2 (0.7) | 0.53d |
Initial aPTT (median, IQR) | 34.8 (5.9) | 33 (5) | 34 (7) | 0.45d |
During treatment | ||||
Highest AST (median, IQR) | 64 (83) | 131 (278) | 58 (50) | <0.01 d |
Number of days until highest value (median, IQR) | 2 (4) | 3 (3) | 1 (5) | 0.43d |
Highest ALT (median, IQR) | 83 (88.5) | 99 (297) | 75 (72) | 0.05 d |
Number of days until highest value (median, IQR) | 3 (4) | 3 (2) | 2.5 (4) | 0.77d |
Highest GGT (median, IQR) | 72.5 (108) | 93 (160) | 66 (99) | 0.16d |
Highest AP (median, IQR) | 71 (30) | 84 (63) | 70 (31) | 0.07d |
Highest total bilirubin (median, IQR) | 1.6 (1.3) | 1.6 (1.4) | 1.5 (1.3) | 0.85d |
Highest aPTT (median, IQR) | 34.8 (6.2) | 38 (6) | 34 (5) | 0.06d |
Outcomes | ||||
Asymptomatic liver dysfunction (n, %) | 10 (17.5%) | 8 (42%) | 2 (5%) | <0.01 c |
Symptomatic liver dysfunction (n,%) | 0 | 0 | 0 | – |
Death (n, %) | 0 | 0 | 0 | – |